Additionally, apelin blockade reduced metastatic tumor size in the lung, liver, and bone by 78.9%, 95.6%, and 96.1%, respectively, as determined by H&E staining, suggesting that inhibiting apelin suppresses prostate cancer metastasis. Here, APLN is linked to prostate carcinoma.